Unknown

Dataset Information

0

Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort.


ABSTRACT: Bisphosphonates are the primary therapy for postmenopausal and glucocorticoid-induced osteoporosis. Case series suggest a potential link between prolonged use of bisphosphonates and low-energy fracture of subtrochanteric or diaphyseal femur as a consequence of oversuppression of bone resorption. Using health care utilization data, we conducted a propensity score-matched cohort study to examine the incidence rates (IRs) and risk of subtrochanteric or diaphyseal femur fractures among oral bisphosphonate users compared with raloxifene or calcitonin users. A Cox proportional hazards model evaluated the risk of these fractures associated with duration of osteoporosis treatment. A total of 104 subtrochanteric or diaphyseal femur fractures were observed among 33,815 patients. The estimated IR of subtrochanteric or diaphyseal femur fractures per 1000 person-years was 1.46 [95% confidence interval (CI) 1.11-1.88] among the bisphosphonate users and 1.43 (95% CI 1.06-1.89) among raloxifene/calcitonin users. No significant association between bisphosphonate use and subtrochanteric or diaphyseal femur fractures was found [hazard ratio (HR)?=?1.03, 95% CI 0.70-1.52] compared with raloxifene/calcitonin. Even with this large study size, we had little precision in estimating the risk of subtrochanteric or diaphyseal femur fractures in patients treated with bisphosphonates for longer than 5 years (HR?=?2.02, 95% CI 0.41-10.00). The occurrence of subtrochanteric or diaphyseal femur fracture was rare. There was no evidence of an increased risk of subtrochanteric or diaphyseal femur fractures in bisphosphonate users compared with raloxifene/calcitonin users. However, this study cannot exclude the possibility that long-term bisphosphonate use may increase the risk of these fractures.

SUBMITTER: Kim SY 

PROVIDER: S-EPMC3179299 | biostudies-literature | 2011 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort.

Kim Seo Young SY   Schneeweiss Sebastian S   Katz Jeffrey N JN   Levin Raisa R   Solomon Daniel H DH  

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20110501 5


Bisphosphonates are the primary therapy for postmenopausal and glucocorticoid-induced osteoporosis. Case series suggest a potential link between prolonged use of bisphosphonates and low-energy fracture of subtrochanteric or diaphyseal femur as a consequence of oversuppression of bone resorption. Using health care utilization data, we conducted a propensity score-matched cohort study to examine the incidence rates (IRs) and risk of subtrochanteric or diaphyseal femur fractures among oral bisphosp  ...[more]

Similar Datasets

| S-EPMC2999980 | biostudies-literature
| S-EPMC3563115 | biostudies-literature
| S-EPMC4254865 | biostudies-literature
| S-EPMC3713078 | biostudies-literature
| S-EPMC4393307 | biostudies-literature
| S-EPMC3387394 | biostudies-literature
| S-EPMC4713232 | biostudies-other
| S-EPMC10020654 | biostudies-literature
| S-EPMC6584163 | biostudies-literature
| S-EPMC6630011 | biostudies-literature